Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
IRVINE, Calif., May 09, 2017 -- Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (NYSE:IMUC). Investors who purchased or otherwise acquired shares between May 1, 2012 and December 11, 2013, inclusive (the “Class Period”), are encouraged to contact the Firm before the June 30, 2017 lead plaintiff motion deadline.
If you purchased ImmunoCellular shares during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may also choose to take no action and remain a passive class member.
According to the Complaint, during the Class Period, ImmunoCellular issued materially false and/or misleading statements and/or failed to disclose: that the Company retained Lidingo Holdings, LLC to publish promotional articles designed to unlawfully promote the Company; and that the market was led to believe that the Company’s clinical studies for its product candidate ICT-107 were going well and the share price was artificially inflated. When this news was announced, ImmunoCellular’s stock price fell materially, which harmed investors according to the Complaint. On April 10, 2017, the SEC announced enforcement actions against numerous individuals and entities, including ImmunoCellular, that engaged in stock promotion schemes.
If you wish to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
